Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ELCC 2019 | Current treatment landscape for ALK-positive NSCLC

Marina Garassino • 12 Apr 2019
ELCC 2019
Lung Cancer Non-Small Cell Lung Cancer Alectinib Brigatinib Crizotinib

In this video, Marina Garassino, MD, of National Cancer Institute of Milan, Milan, Italy, presents the currently available drugs against ALK-positive treating non-small cell lung cancer (NSCLC): crizotinib, ceritinib, alectinib and brigatinib. Speaking at the European Lung Cancer Congress (ELCC) 2019, held in Geneva, Switzerland, Dr Garassino reports that all agents demonstrate different toxicity profiles and stresses the need for further research in order to single out the most effective drug.

More from Marina Garassino

3:25
PACIFIC 6: durvalumab after sCRT in patients with NSCLC
Marina Garassino • 18 Mar 2021
4:28
Combining chemotherapy and immunotherapy: key trials in lung cancer
Marina Garassino • 18 Mar 2021
3:04
TERAVOLT: outcomes for patients with COVID-19 and lung cancer
Marina Garassino • 18 Mar 2021
1:43
Novel targets for NSCLC
Marina Garassino • 18 Mar 2021

Related Videos

2:38
Phase I trial of binimetinib and pembrolizumab in NSCLC
Natasha Leighl • 17 Apr 2024
2:43
CHRYSALIS: amivantamab in wild-type, pre-treated NSCLC
Natasha Leighl • 17 Apr 2024
3:03
BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies
Sanjay Popat • 19 Apr 2024
2:09
Is there a role for radiotherapy in extensive-stage SCLC?
Clive Peedell • 18 Apr 2024
The content of VJOncology is intended for healthcare professionals